Evidence map›Paper›PMID 33556653›Full record

ArticleVirology2021

The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters.

Charles B Stauft, Christopher Z Lien, Prabhuanand Selvaraj, Shufeng Liu, Tony T Wang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2.Journal of microbiology and biotechnology · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charles B StauftLaboratory of Vector-Borne Diseases, Division of Viral Products, Office of Vaccine Research and Review, Food and Drug Administration, White Oak, MD, USA.
Christopher Z LienLaboratory of Vector-Borne Diseases, Division of Viral Products, Office of Vaccine Research and Review, Food and Drug Administration, White Oak, MD, USA.
Prabhuanand SelvarajLaboratory of Vector-Borne Diseases, Division of Viral Products, Office of Vaccine Research and Review, Food and Drug Administration, White Oak, MD, USA.
Shufeng LiuLaboratory of Vector-Borne Diseases, Division of Viral Products, Office of Vaccine Research and Review, Food and Drug Administration, White Oak, MD, USA.
Tony T WangLaboratory of Vector-Borne Diseases, Division of Viral Products, Office of Vaccine Research and Review, Food and Drug Administration, White Oak, MD, USA. Electronic address: Tony.Wang@hhs.fda.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dynamic tracking of variant frequencies among viruses circulating in the global pandemic has revealed the emergence and dominance of a D614G mutation in the SARS-CoV-2 spike protein. To address whether pandemic SARS-CoV-2 G614 variant has evolved to become more pathogenic, we infected adult hamsters (>10 months old) with two natural SARS-CoV-2 variants carrying either D614 or G614 spike protein to mimic infection of the adult/elderly human population. Hamsters infected by the two variants exhibited comparable viral loads and pathology in lung tissues as well as similar amounts of virus shed in nasal washes. Altogether, our study does not find that naturally circulating D614 and G614 SARS-CoV-2 variants differ significantly in pathogenicity in hamsters.

Indexed as

AnimalsAntibodies, NeutralizingChlorocebus aethiopsCOVID-19Disease Models, AnimalFemaleLungMaleMesocricetusMutationSARS-CoV-2Spike Glycoprotein, CoronavirusVero CellsViral LoadWeight LossAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CoronavirusCOVID-19Hamster modelSARS-CoV-2Severe acute respiratory syndromeSpike proteinSyrian hamsters

Identifiers

PMID33556653
PMCPMC7830243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.